Last reviewed · How we verify
4SCAR T cells
At a glance
| Generic name | 4SCAR T cells |
|---|---|
| Sponsor | Shenzhen Geno-Immune Medical Institute |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- DLL3 CAR-T Therapy Targeting Brain Tumors (PHASE1, PHASE2)
- Intervention of Bladder Cancer by CAR-T (PHASE1, PHASE2)
- Study on GD2 Positive Solid Tumors by 4SCAR-GD2 (PHASE1, PHASE2)
- Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells (PHASE1, PHASE2)
- Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma (PHASE1)
- CAR-T Cells Targeting Autoimmune Diseases (PHASE1, PHASE2)
- 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma (PHASE1, PHASE2)
- PSMA-specific CAR-T Cell Therapy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 4SCAR T cells CI brief — competitive landscape report
- 4SCAR T cells updates RSS · CI watch RSS
- Shenzhen Geno-Immune Medical Institute portfolio CI